Covered recipient · General Payments record
MINERVA M ELLIS
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2019–2025
$688.38
- Reported across 31 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $303.24 | 15 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $61.51 | 3 |
| Novo Nordisk AS | $36.18 | 2 |
| Exact Sciences Corporation | $32.63 | 1 |
| Gilead Sciences, Inc. | $23.11 | 1 |
| Abbott Laboratories | $23.03 | 1 |
| Seqirus USA Inc | $21.90 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $21.22 | 1 |
| PFIZER INC. | $20.22 | 1 |
| ABBVIE INC. | $17.13 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.85 | 1 |
| Merck Sharp & Dohme Corporation | $15.29 | 1 |
| Amgen Inc. | $14.17 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.03 | 01/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240893496 | CMS |
| ABBVIE INC. | $17.13 | 11/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201814991 | CMS |
| Amgen Inc. | $14.17 | 09/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1227141360 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $21.22 | 05/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1225528114 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.85 | 10/23/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1222849780 | CMS |
| Exact Sciences Corporation | $32.63 | 01/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1235410855 | CMS |
| Gilead Sciences, Inc. | $23.11 | 10/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234493204 | CMS |
| Lilly USA, LLC | $22.27 | 05/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186777223 | CMS |
| Lilly USA, LLC | $19.71 | 05/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186826448 | CMS |
| Lilly USA, LLC | $19.53 | 06/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186839715 | CMS |
| Merck Sharp & Dohme LLC | $15.29 | 09/18/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1238192704 | CMS |
| Novo Nordisk Inc | $17.84 | 01/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188567602 | CMS |
| Novo Nordisk Inc | $18.34 | 12/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188714499 | CMS |
| PFIZER INC. | $20.22 | 09/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1229441276 | CMS |
| Seqirus USA Inc | $21.90 | 09/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1201082409 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2023, 2024, 2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.